trending Market Intelligence /marketintelligence/en/news-insights/trending/xyhfga_46zyjdgisvby0za2 content esgSubNav
In This List

Concordia International appoints director

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


Concordia International appoints director

Canada-based Concordia International Corp. said it appointed Frances Cloud to its board of directors, effective Nov. 1.

Cloud has worked in the pharmaceutical sector over 20 years, having served as an analyst and investment banker for companies including Nomura International, IMI Securities and Swiss Bank Corp., according to a news release.

She founded consulting firm Pharmacloud Research in 2009, to cover the generic drug industry in Europe, India and the Middle East and North Africa region.

Cloud's expertise in the European pharmaceutical industry will help the Concordia buy targeted products and companies and expand its product portfolio, said Concordia CEO Graeme Duncan.

Concordia International, a specialty pharmaceutical company, plans to change its name to Advanz Pharma following a recapitalization.